Martin Lukáš

974 total citations
30 papers, 304 citations indexed

About

Martin Lukáš is a scholar working on Genetics, Immunology and Surgery. According to data from OpenAlex, Martin Lukáš has authored 30 papers receiving a total of 304 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 13 papers in Immunology and 10 papers in Surgery. Recurrent topics in Martin Lukáš's work include Inflammatory Bowel Disease (17 papers), Microscopic Colitis (9 papers) and Biosimilars and Bioanalytical Methods (7 papers). Martin Lukáš is often cited by papers focused on Inflammatory Bowel Disease (17 papers), Microscopic Colitis (9 papers) and Biosimilars and Bioanalytical Methods (7 papers). Martin Lukáš collaborates with scholars based in Czechia and United Kingdom. Martin Lukáš's co-authors include Milan Lukáš, Martin Bortlík, Naděžda Machková, Dana Ďuricová, Karin Malíčková, Veronika Hrubá, Katarína Mitrová, Pavel Kohout, Martin Kolář and Olga Shonová and has published in prestigious journals such as Gastroenterology, Gastrointestinal Endoscopy and Inflammatory Bowel Diseases.

In The Last Decade

Martin Lukáš

25 papers receiving 304 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Martin Lukáš Czechia 9 195 150 120 108 103 30 304
Evelien Humblet Belgium 5 88 0.5× 185 1.2× 44 0.4× 143 1.3× 68 0.7× 10 248
Annick Moens Belgium 8 67 0.3× 132 0.9× 55 0.5× 115 1.1× 86 0.8× 17 207
E. А. Belousova Russia 7 41 0.2× 240 1.6× 76 0.6× 216 2.0× 95 0.9× 36 328
Antonio López-San Román Spain 11 74 0.4× 157 1.0× 116 1.0× 166 1.5× 138 1.3× 29 368
Aimee Blake United Kingdom 8 100 0.5× 195 1.3× 81 0.7× 152 1.4× 109 1.1× 23 286
Laura Armengol‐Debeir France 8 43 0.2× 272 1.8× 33 0.3× 171 1.6× 169 1.6× 15 355
Arabinda Pal United Kingdom 5 194 1.0× 51 0.3× 220 1.8× 38 0.4× 160 1.6× 8 335
Kimberly N. Weaver United States 8 49 0.3× 189 1.3× 37 0.3× 157 1.5× 84 0.8× 22 316
E Iglesias-Flores Spain 8 72 0.4× 246 1.6× 36 0.3× 188 1.7× 131 1.3× 23 320
Khadija Chaudrey United States 4 70 0.4× 248 1.7× 34 0.3× 219 2.0× 102 1.0× 15 314

Countries citing papers authored by Martin Lukáš

Since Specialization
Citations

This map shows the geographic impact of Martin Lukáš's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Lukáš with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Lukáš more than expected).

Fields of papers citing papers by Martin Lukáš

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Lukáš. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Lukáš. The network helps show where Martin Lukáš may publish in the future.

Co-authorship network of co-authors of Martin Lukáš

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Lukáš. A scholar is included among the top collaborators of Martin Lukáš based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Lukáš. Martin Lukáš is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lukáš, Martin, et al.. (2025). VEDOLIZUMAB PLUS CURCUMIN-QINGDAI FOR PATIENTS WITH ULCERATIVE COLITIS. Inflammatory Bowel Diseases. 31(Supplement_1). S74–S74.
2.
Ďuricová, Dana, Martin Lukáš, Naděžda Machková, et al.. (2022). Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients. Journal of Crohn s and Colitis. 16(9). 1347–1353. 8 indexed citations
3.
Lukáš, Martin, et al.. (2022). ENDOSCOPIC STRICTUROTOMY – A NOVEL THERAPEUTIC MODALITY FOR IBD-RELATED STRICTURES: FIRST EUROPEAN EXPERIENCE. Inflammatory Bowel Diseases. 28(Supplement_1). S40–S41.
4.
5.
Lukáš, Martin, Martin Kolář, O Ryska, et al.. (2021). A novel postgraduate endoscopic course using a large animal model of secondary Crohn's disease stricture. Surgical Endoscopy. 35(6). 3199–3204. 1 indexed citations
6.
Ďuricová, Dana, Martin Lukáš, Naděžda Machková, et al.. (2021). Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study. Inflammatory Bowel Diseases. 28(10). 1506–1512. 16 indexed citations
7.
Lukáš, Martin, Martin Kolář, O Ryska, et al.. (2020). Novel porcine model of Crohn's disease anastomotic stricture suitable for evaluation and training of advanced endoscopic techniques. Gastrointestinal Endoscopy. 93(1). 250–256. 6 indexed citations
8.
Lukáš, Martin, Karin Malíčková, Martin Bortlík, et al.. (2020). Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre. Journal of Crohn s and Colitis. 14(7). 915–919. 42 indexed citations
9.
Malíčková, Karin, Martin Bortlík, Dana Ďuricová, et al.. (2020). Telemedicine and inflammatory bowel disease – results of the IBD Assistant pilot project. 74(1). 18–27. 1 indexed citations
10.
Kolář, Martin, Dana Ďuricová, Martin Bortlík, et al.. (2019). Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice. 73(1). 25–31. 3 indexed citations
11.
Kolář, Martin, Martin Bortlík, Dana Ďuricová, et al.. (2019). Mo1919 – Ustekinumab Efficiency As a Higher-Line Therapy in Association with Serum Levels in Patients with Crohn’s Disease. Gastroenterology. 156(6). S–886. 2 indexed citations
12.
Ďuricová, Dana, Eva Dvořáková, Ondřej Hradský, et al.. (2018). Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation. Inflammatory Bowel Diseases. 25(4). 789–796. 61 indexed citations
13.
Bortlík, Martin, Naděžda Machková, Veronika Hrubá, et al.. (2018). Efficacy of ustekinumab in a patient refractory to other biological treatment. 72(1). 47–49.
14.
Ďuricová, Dana, Eva Dvořáková, Ondřej Hradský, et al.. (2018). Vliv expozice anti-TNF-alfa in utero na vývoj imunitního systému exponovaných dětí – kontrolovaná multicentrická studie. 72(6). 479–485.
15.
Teplan, Vladimı́r, et al.. (2017). Obesity and kidney. 71(6). 510–516. 1 indexed citations
16.
Kolář, Martin, Dana Ďuricová, Martin Bortlík, et al.. (2016). Biosimilar infliximab in anti-TNF-naïve IBD patients – 1-year clinical follow-up. 70(6). 514–522. 1 indexed citations
17.
Bortlík, Martin, Dana Ďuricová, Naděžda Machková, et al.. (2015). Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scandinavian Journal of Gastroenterology. 51(2). 196–202. 39 indexed citations
18.
Malíčková, Karin, Dana Ďuricová, Martin Bortlík, et al.. (2015). Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease. Biologicals. 44(1). 33–36. 25 indexed citations
19.
Ďuricová, Dana, Martin Bortlík, Naděžda Machková, et al.. (2015). 283 Deep Remission in Crohn's Disease Does Not Prevent Disease Relapse After Withdrawal of Anti-TNFa Therapy. Gastroenterology. 148(4). S–61. 2 indexed citations
20.
Bortlík, Martin, Naděžda Machková, Dana Ďuricová, et al.. (2013). Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study. Scandinavian Journal of Gastroenterology. 48(8). 951–958. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Evelien Humblet Breakdown of academic impact, for papers by Annick Moens Breakdown of academic impact, for papers by E. А. Belousova Breakdown of academic impact, for papers by Antonio López-San Román Breakdown of academic impact, for papers by Aimee Blake Breakdown of academic impact, for papers by Laura Armengol‐Debeir Breakdown of academic impact, for papers by Arabinda Pal Breakdown of academic impact, for papers by Kimberly N. Weaver Breakdown of academic impact, for papers by E Iglesias-Flores Breakdown of academic impact, for papers by Khadija Chaudrey
Rankless by CCL
2026